Old Web
English
Sign In
Acemap
>
authorDetail
>
Giridharan Ramsingh
Giridharan Ramsingh
Exelixis
Pathology
Atezolizumab
Cabozantinib
Medicine
Angiogenesis
3
Papers
9
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
P1.01-113 Phase 1b Trial of Cabozantinib or Cabozantinib Plus Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
2019
Journal of Thoracic Oncology
F. Lim
S. Ponce
Shiven B. Patel
C. Van Herpen
C. Kurkjian
Yanyan Lou
Y. Liu
Giridharan Ramsingh
Sumanta K. Pal
Joel W. Neal
Show All
Source
Cite
Save
Citations (1)
Phase Ib (COSMIC-021) trial of cabozantinib (C) in urothelial carcinoma (UC) or C in combination with atezolizumab (A) in patients (pts) with UC, castrate resistant prostate cancer (CRPC) or renal cell carcinoma (RCC).
2019
Journal of Clinical Oncology
Sumanta K. Pal
Ulka N. Vaishampayan
Daniel Castellano
Andrea Necchi
Carla M.L. van Herpen
Giridharan Ramsingh
Yohann Loriot
Neeraj Agarwal
Show All
Source
Cite
Save
Citations (5)
Phase Ib trial of cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with advanced hepatocellular carcinoma (HCC), gastric or gastroesophageal junction cancer (GC/GEJC), or colorectal cancer (CRC).
2019
Journal of Clinical Oncology
Kristen Spencer
Giridharan Ramsingh
Nehal Mohamed
Sumanta K. Pal
Lorenza Rimassa
Show All
Source
Cite
Save
Citations (3)
1